Effect of Yttrium-90 microsphere transarterial radioembolization for unresectable primary liver cancer: a Meta-analysis

doi:10.3877/cma.j.issn.2095-3232.2014.06.006

Abstract

Abstract:

Objective

To assess the effect of transarterial radioembolization (TARE) using Yttrium-90 microsphere for unresectable primary liver cancer (PLC).

Methods

Literature from January 2009 to December 2013 were searched in the Medline, Web of Science, Cochrane Controlled Trial Register (CENTRAL) and EMBASE databases with the search terms mainly including: radioembolization, transarterial radioembolization, TARE, selective internal radiation therapy, SIRT, Yttrium-90, 90Y, chemoembolization, transarterial chemoembolization (TACE), hepatocellular carcinoma, HCC, liver cancer, liver tumor, liver neoplasm and with the assistance of manual searching. Data of the included literature were merged and the patients were divided into TARE group and TACE group according to the different treatments. The data of tumor therapeutic response and 1-, 2-, 3-year survival rates were collected. Literature heterogeneity inspection was conducted by Q test. Publication bias was tested by drawing funnel plot and linear regression model.

Results

Five articles were included after screening with the quality of medium to high. There were totally 591 cases with 292 in TARE group and 299 in TACE group. Meta-analysis was conducted using fixed effect model. Tumor therapeutic response was observed better in TARE group, compared with that in TACE group (RR=1.50, P<0.05). The 2-, 3-year survival rates in TARE group were significantly higher than those in TACE group (RR=1.56, 2.04; P<0.05).

Conclusions

Compared with TACE, TARE can obviously improve the tumor therapeutic response rate and long-term survival rate of patients with unresectable PLC.

Key words: Carcinoma, hepatocellular, Yttrium, radioisotopes, Radiotherapy, Chemoembolization, therapeutic, Meta-analysis

Muxing Li, Xufeng Zhang, Jiwen Cheng, Ying Zhu, Wanli Wang, Jian Dong, Zhida Long, Yi Lyu. Effect of Yttrium-90 microsphere transarterial radioembolization for unresectable primary liver cancer: a Meta-analysis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2014, 03(06): 354-358.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2014.06.006

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2014/V03/I06/354

Figures/Tables 5

References 17

[1]	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[2]	Meza-Junco J, Montano-Loza AJ, Liu DM, et al. Locoregional radiological treatment for hepatocellular carcinoma: which, when and how?[J]. Cancer Treat Rev, 2012, 38(1):54-62.
[3]	沈海洋，刘瑞宝．钇90微球经肝动脉选择性放射治疗肝肿瘤应用现状[J]．实用肿瘤学杂志，2009, 23(6):582-585.
[4]	Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds[J]. Eur J Nucl Med Mol Imaging, 2011, 38(7):1393-1406.
[5]	Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres[J]. Hepatology, 2009, 49(4):1185-1193.
[6]	Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization[J]. Am J Transplant, 2009, 9(8):1920-1928.
[7]	Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2010, 21(2):224-230.
[8]	Lance C, Mclennan G, Obuchowski N, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2011, 22(12):1697-1705.
[9]	Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2011, 140(2):497-507.
[10]	Moreno-Luna LE, Yang JD, Sanchez W, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2013, 36(3):714-723.
[11]	吕毅，张谞丰．肝细胞肝癌的多学科协作组概念及其实践[J/CD]．中华肝脏外科手术学电子杂志，2013, 2(1):1-3.
[12]	Wigg AJ, Palumbo K, Wigg DR. Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modeling projections indicate reconsideration of its use[J]. J Gastroenterol Hepatol, 2010, 25(4):664-671.
[13]	Sangro B, Salem R, Kennedy A, et al. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations[J]. Am J Clin Oncol, 2011, 34(4):422-431.
[14]	Ray CJ Jr, Battaglia C, Libby AM, et al. Interventional radiologic treatment of hepatocellular carcinoma: a cost analysis from the payer perspective[J]. J Vasc Interv Radiol, 2012, 23(3):306-314.
[15]	李少华，陈敏山．经皮穿刺肝动脉化疗栓塞在肝细胞肝癌根治性切除术后的应用[J/CD]．中华肝脏外科手术学电子杂志，2013, 2(5):281-284.
[16]	Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma[J]. J Hepatol, 2012, 56(2):464-473.
[17]	刘允怡，赖俊雄，刘晓欣．钇90微球治疗原发性肝癌[J]．临床肝胆病杂志，2011, 27(4):348-350.

研究作者	发表时间（年份）	治疗方法（例）		随访时间（月）		NOS评分（分）	质量
研究作者	发表时间（年份）	TARE	TACE	TARE	TACE	NOS评分（分）	质量
Lewandowski RJ,et al^[6]	2009	43	43	34^a	52^a	6	高
Kooby DA,et al^[7]	2010	27	44	6	6	5	中
Lance C,et al^[8]	2011	38	35	12	16	5	中
Salem R,et al^[9]	2011	123	122	23	33	7	高
Moreno-Luna LE，et al^[10]	2013	61	55	>52	>52	5	中

研究作者	发表时间（年份）	治疗方法（例）		随访时间（月）		NOS评分（分）	质量
研究作者	发表时间（年份）	TARE	TACE	TARE	TACE	NOS评分（分）	质量
Lewandowski RJ,et al^[6]	2009	43	43	34^a	52^a	6	高
Kooby DA,et al^[7]	2010	27	44	6	6	5	中
Lance C,et al^[8]	2011	38	35	12	16	5	中
Salem R,et al^[9]	2011	123	122	23	33	7	高
Moreno-Luna LE，et al^[10]	2013	61	55	>52	>52	5	中

Please choose a citation manager

Content to export